Table 1.

Selected clinical trials of atezolizumab in bladder cancer

StudyDisease stateTrial armsPrimary outcomesTrial status
NCT02302807, IMvigor211, phase III
  • –Locally advanced or metastatic BC

  • –Second line (failed platinum)

  • –Atezolizumab

  • –Investigator's choice chemotherapy (vinflunine, paclitaxel, or docetaxel)

OSAccrual complete
NCT02807636, IMvigor130, phase III
  • –Locally advanced or metastatic BC

  • –First line (platinum ineligible)

  • –Atezolizumab + gemcitabine/carboplatin

  • –Placebo + gemcitabine/carboplatin

PFS, OSCurrently recruiting patients
NCT02450331, IMvigor010, phase III
  • –Muscle-invasive BC, postcystectomy (≥T3 if no neoadjuvant chemo, ≥T2 if neoadjuvant chemo)

  • –Atezolizumab × 1 year

  • –Observation

DFSCurrently recruiting patients
NCT02662309, ABACUS, phase II
  • –Muscle-invasive BC, precystectomy, cisplatin ineligible

Atezolizumab × 2 cyclesResponse rate, immune monitoringCurrently recruiting patients
NCT02451423, phase II
  • –BCG-refractory non-muscle–invasive BC, precystectomy

  • –Muscle-invasive BC, precystectomy, cisplatin ineligible

Sequential dosing, 3-week cycles of atezolizumabResponse rate, immune monitoringCurrently recruiting patients
NCT02792192, GU123, phase Ib/II
  • –BCG-refractory non-muscle–invasive BC

BCG + atezolizumabDFSCurrently recruiting patients
  • Abbreviations: BC, bladder cancer; chemo, chemotherapy; DFS, disease-free survival.